OBJECTIVE: The Restoring Insulin Secretion (RISE) Adult Medication Study compared pharmacological approaches targeted to improve β-cell function in individuals with impaired glucose tolerance (IGT) or treatment-naive type 2 diabetes of <12 months duration. RESEARCH DESIGN AND METHODS: A total of 267 adults with IGT (n = 197, 74%) or recently diagnosedtype 2 diabetes (n = 70, 26%) were studied. Participants were randomized to receive 12 months of metformin alone, 3 months of insulin glargine with a target fasting glucose <5 mmol/L followed by 9 months of metformin, 12 months of liraglutide combined with metformin, or 12 months of placebo. β-Cell function was assessed using hyperglycemic clamps at baseline, 12 months (on treatment), and 15 months (3 months off treatment). The primary outcome was β-cell function at 15 months compared with baseline. RESULTS: All three active treatments produced on-treatment reductions in weight and improvements in HbA1c compared with placebo; the greatest reductions were seen in the liraglutide plus metformin group. At 12 months, glucose-stimulated C-peptide responses improved in the three active treatment groups and were greatest in the liraglutide plus metformin group, but the arginine-stimulated incremental C-peptide response was reduced in the liraglutide plus metformin group. Despite on-treatment benefits, 3 months after treatment withdrawal there were no sustained improvements in β-cell function in any treatment group. CONCLUSIONS: In adults with IGT or recently diagnosed type 2 diabetes, interventions that improved β-cell function during active treatment failed to produce persistent benefits after treatment withdrawal. These observations suggest that continued intervention may be required to alter the progressive β-cell dysfunction in IGT or early type 2 diabetes.
RCT Entities:
OBJECTIVE: The Restoring Insulin Secretion (RISE) Adult Medication Study compared pharmacological approaches targeted to improve β-cell function in individuals with impaired glucose tolerance (IGT) or treatment-naive type 2 diabetes of <12 months duration. RESEARCH DESIGN AND METHODS: A total of 267 adults with IGT (n = 197, 74%) or recently diagnosed type 2 diabetes (n = 70, 26%) were studied. Participants were randomized to receive 12 months of metformin alone, 3 months of insulinglargine with a target fasting glucose <5 mmol/L followed by 9 months of metformin, 12 months of liraglutide combined with metformin, or 12 months of placebo. β-Cell function was assessed using hyperglycemic clamps at baseline, 12 months (on treatment), and 15 months (3 months off treatment). The primary outcome was β-cell function at 15 months compared with baseline. RESULTS: All three active treatments produced on-treatment reductions in weight and improvements in HbA1c compared with placebo; the greatest reductions were seen in the liraglutide plus metformin group. At 12 months, glucose-stimulated C-peptide responses improved in the three active treatment groups and were greatest in the liraglutide plus metformin group, but the arginine-stimulated incremental C-peptide response was reduced in the liraglutide plus metformin group. Despite on-treatment benefits, 3 months after treatment withdrawal there were no sustained improvements in β-cell function in any treatment group. CONCLUSIONS: In adults with IGT or recently diagnosed type 2 diabetes, interventions that improved β-cell function during active treatment failed to produce persistent benefits after treatment withdrawal. These observations suggest that continued intervention may be required to alter the progressive β-cell dysfunction in IGT or early type 2 diabetes.
Authors: Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: William C Knowler; Richard F Hamman; Sharon L Edelstein; Elizabeth Barrett-Connor; David A Ehrmann; Elizabeth A Walker; Sarah E Fowler; David M Nathan; Steven E Kahn Journal: Diabetes Date: 2005-04 Impact factor: 9.461
Authors: Anny H Xiang; Ruth K Peters; Siri L Kjos; Aura Marroquin; Jose Goico; Cesar Ochoa; Miwa Kawakubo; Thomas A Buchanan Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Jaana Lindström; Anne Louheranta; Marjo Mannelin; Merja Rastas; Virpi Salminen; Johan Eriksson; Matti Uusitupa; Jaakko Tuomilehto Journal: Diabetes Care Date: 2003-12 Impact factor: 19.112
Authors: John M Lachin; Costas A Christophi; Sharon L Edelstein; David A Ehrmann; Richard F Hamman; Steven E Kahn; William C Knowler; David M Nathan Journal: Diabetes Date: 2007-04 Impact factor: 9.461
Authors: Thomas A Buchanan; Anny H Xiang; Ruth K Peters; Siri L Kjos; Aura Marroquin; Jose Goico; Cesar Ochoa; Sylvia Tan; Kathleen Berkowitz; Howard N Hodis; Stanley P Azen Journal: Diabetes Date: 2002-09 Impact factor: 9.461
Authors: Kieren J Mather; Ashley H Tjaden; Adam Hoehn; Kristen J Nadeau; Thomas A Buchanan; Steven E Kahn; Silva A Arslanian; Sonia Caprio; Karen M Atkinson; Melanie Cree-Green; Kristina M Utzschneider; Sharon L Edelstein Journal: Am J Physiol Endocrinol Metab Date: 2021-03-01 Impact factor: 4.310
Authors: Babak Mokhlesi; Ashley H Tjaden; Karla A Temple; Sharon L Edelstein; Susan Sam; Kristen J Nadeau; Tamara S Hannon; Shalini Manchanda; Kieren J Mather; Steven E Kahn; David A Ehrmann; Eve Van Cauter Journal: Diabetes Care Date: 2021-02-05 Impact factor: 19.112
Authors: Silva A Arslanian; Laure El Ghormli; Joon Young Kim; Ashley H Tjaden; Elena Barengolts; Sonia Caprio; Tamara S Hannon; Kieren J Mather; Kristen J Nadeau; Kristina M Utzschneider; Steven E Kahn Journal: Diabetes Care Date: 2021-01-12 Impact factor: 19.112
Authors: Petter Bjornstad; Kimberly L Drews; Sonia Caprio; Rose Gubitosi-Klug; David M Nathan; Bereket Tesfaldet; Jeanie Tryggestad; Neil H White; Philip Zeitler Journal: N Engl J Med Date: 2021-07-29 Impact factor: 91.245